AstraZeneca's vaccine hit its first roadblock with Indian regulators. Will lingering doubts derail its plans elsewhere?
British drugmaker AstraZeneca is already running behind early competitors in the hunt for a Covid-19 vaccine with interim data that have received less-than-stellar feedback. With those data in hand, India has said “no thanks” to an early approval for the shot, potentially setting the stage for even more setbacks.
On Tuesday, Indian regulators refused to grant AstraZeneca’s adenovirus-based Covid-19 vaccine an emergency use authorization based on a dearth of adequate safety and efficacy data, Reuters reported, citing local broadcaster NDTV.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters